Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma.

MLA

Rognoni, Carla, et al. “Cost-Effectiveness Analysis of Personalised versus Standard Dosimetry for Selective Internal Radiation Therapy with TheraSphere in Patients with Hepatocellular Carcinoma.” Frontiers in Oncology, vol. 12, Aug. 2022, pp. 1–10. EBSCOhost, https://doi.org/10.3389/fonc.2022.920073.

APA

Rognoni, C., Barcellona, M. R., Bargellini, I., Bavetta, M. G., Bellò, M., Brunetto, M., Carucci, P., Cioni, R., Crocetti, L., D, A. F., D, A. M., Deagostini, S., Deandreis, D., De Simone, P., Doriguzzi, A., Finessi, M., Fonio, P., Grimaldi, S., Ialuna, S., & Lagattuta, F. (2022). Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma. Frontiers in Oncology, 12, 1–10. https://doi.org/10.3389/fonc.2022.920073

Chicago

Rognoni, Carla, Maria Rosa Barcellona, Irene Bargellini, Maria Grazia Bavetta, Marilena Bellò, Maurizia Brunetto, Patrizia Carucci, et al. 2022. “Cost-Effectiveness Analysis of Personalised versus Standard Dosimetry for Selective Internal Radiation Therapy with TheraSphere in Patients with Hepatocellular Carcinoma.” Frontiers in Oncology 12 (August): 1–10. doi:10.3389/fonc.2022.920073.